AD, according to the NIA-AA conceptualisation, refers to specific neuropathological changes, and is “defined” by abnormal levels of the biomarkers pathological tau and Aβ (Jack et al. 2018, pp. This evidence concerns the gene MAPT and Alzheimer disease.